MSB0010718C

DRUG2 trials

Sponsors

Istituto Oncologico Veneto IRCCS, Merck

Conditions

Triple Negative Breast Neoplasmsnon-small cell lung cancer

Phase 3

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

Active, not recruitingNL-OMON42011

Mercknon-small cell lung cancer

Start: 2016-01-28Target: 20Updated: 2024-02-28

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

CompletedNCT02926196

Istituto Oncologico Veneto IRCCSTriple Negative Breast Neoplasms

Start: 2016-06-17End: 2025-10-09Updated: 2025-12-12

Related Papers

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer

Clinical Cancer Research2026-07-17

Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial.

Journal of Clinical Oncology2026-05-27

A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.

Journal of Clinical Oncology2024-06-0527 citations

Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.

Journal of Clinical Oncology2020-05-2030 citations